A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

Inclusion Criteria

• •Informed consent from parent(s) or legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
• •Male or female, aged 10 to below 18 years at the day of randomisation
• •HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)
• •Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with:
• •stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening) or
• •stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin is defined as basal insulin treatment equal to or more than 30 days prior to screening, compared to the dose at screening, dose adjustments of ± 25% are allowed) or
• •stable dose of basal insulin